Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Seres Therapeutics reported its first quarter 2026 financial results and provided business updates, including an expected clinical readout from an investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis. The company is advancing its live biotherapeutic programs in inflammatory and immune diseases, including SER-155 and SER-603.
Seres Therapeutics, a live biotherapeutics company, reported its first quarter 2026 financial results. The company is advancing its live biotherapeutic programs in inflammatory and immune diseases. A clinical readout from an investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis is expected in the coming weeks. The study, conducted in collaboration with Memorial Sloan Kettering Cancer Center, has completed enrollment with 15 patients. Seres is also conducting IND-enabling activities for SER-603, a potential treatment for inflammatory bowel disease. The company is seeking partnerships and other sources of capital to support the continued development of its pipeline programs.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.